Filing Details

Accession Number:
0000899243-19-000971
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2019-01-10 16:44:12
Reporting Period:
2018-12-03
Accepted Time:
2019-01-10 16:44:12
Original Submission Date:
2018-12-04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1707502 Solid Biosciences Inc. SLDB Biological Products, (No Disgnostic Substances) (2836) 900943402
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1727552 Alvaro Pedro Amorrortu C/O Solid Biosciences Inc.
141 Portland Street, 5Th Floor
Cambridge MA 02139
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-12-03 3,007 $30.20 168,739 No 4 S Direct
Common Stock Disposition 2018-12-03 5,693 $31.44 163,046 No 4 S Direct
Common Stock Disposition 2018-12-03 300 $32.38 162,746 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 29, 2018.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.94, inclusive. The reporting person undertakes to provide to the issuer, anysecurity holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.04 to $31.91, inclusive. The reporting person undertakes to provide to the issuer, anysecurity holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.03 to $32.56, inclusive. The reporting person undertakes to provide to the issuer, anysecurity holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form.
  5. Amendment corrects arithmetical error as to number of securities in Column 5 of Table I.